
Validea's guru fundamental report rates Lam Research Corporation (LRCX), a large-cap semiconductor stock, at 86% using its Warren Buffett-inspired 'Patient Investor' model, the highest among 22 strategies tracked. This strong rating signifies LRCX's alignment with criteria for predictable profitability, low debt, and reasonable valuation, indicating potential interest for long-term, value-focused investors, despite a noted 'Fail' in Return on Total Capital.
Lam Research Corporation (LRCX) screens strongly according to Validea's 'Patient Investor' model, which is based on Warren Buffett's investment principles, achieving a score of 86%. This rating, the highest among 22 strategies, indicates a significant alignment with criteria favoring long-term predictable profitability, low debt, and reasonable valuation. The analysis highlights that LRCX, a large-cap growth stock in the semiconductor industry, passes key fundamental tests including Earnings Predictability, Debt Service, Free Cash Flow, and Share Repurchase, suggesting a financially sound operation with a shareholder-friendly capital return policy. However, the model registers a notable 'Fail' on the Return on Total Capital metric, pointing to a potential area of inefficiency in how the company utilizes its complete capital base, even as its Return on Equity passes the test.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment